KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Cost of Revenue (2016 - 2025)

West Pharmaceutical Services' Cost of Revenue history spans 17 years, with the latest figure at $501.1 million for Q4 2025.

  • For Q4 2025, Cost of Revenue rose 5.45% year-over-year to $501.1 million; the TTM value through Dec 2025 reached $2.0 billion, up 3.98%, while the annual FY2025 figure was $2.0 billion, 3.98% up from the prior year.
  • Cost of Revenue for Q4 2025 was $501.1 million at West Pharmaceutical Services, down from $510.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $510.3 million in Q3 2025 and bottomed at $398.8 million in Q1 2021.
  • The 5-year median for Cost of Revenue is $456.4 million (2023), against an average of $454.6 million.
  • The largest annual shift saw Cost of Revenue rose 23.01% in 2021 before it increased 0.14% in 2022.
  • A 5-year view of Cost of Revenue shows it stood at $430.2 million in 2021, then rose by 3.81% to $446.6 million in 2022, then rose by 1.61% to $453.8 million in 2023, then rose by 4.72% to $475.2 million in 2024, then increased by 5.45% to $501.1 million in 2025.
  • Per Business Quant, the three most recent readings for WST's Cost of Revenue are $501.1 million (Q4 2025), $510.3 million (Q3 2025), and $492.6 million (Q2 2025).